Clin. Exp. Obstet. Gynecol. – ISSN: 0390-6663, XLIII, n. 2, 2016, doi: 10.12891\/ceog2118.2016<\/p>\n
S. Zervoudis1<\/sup>, G. Iatrakis2<\/sup>, E. Tomara3<\/sup>, A. Bothou3<\/sup>, P. Peitsidis2<\/sup>, G. Mastorakos4<\/sup> Summary<\/strong>
\n
\n1<\/sup> Rea Hospital Breast Dept, Technological Educational Institute of Athens, Athens, 2<\/sup> Department of Obstetrics & Gynecology, Technological Educational Institute of Athens, Athens, 3<\/sup> University of Athens, Midwifery Department, Technological Educational Institute of Athens, Athens, 4<\/sup> University of Athens, Clinical Endocrinology, Aretaieio Hospital, Athens (Greece)<\/p>\n
\nAim: The aim of this study was to determine the potential therapeutic benefit of a single administration of a GnRH analogue in premenopausal women presenting large functional ovarian cysts (FOCs) (diameter > five cm). Materials and Methods: Fifty-one patients (median age 37.4 years) diagnosed with ovarian cysts, presumed benign based on transvaginal and\/or transabdominal ultrasound, were divided in three study groups. Patients of group A received no medication whereas patients of groups B and C were treated with a single administration of a GnRH analogue and combined oral contraceptives, respectively. Patients were re-examined after a three-month period. Three of the 51 patients were lost in follow-up or stopped the treatment. Results: Complete resolution of the ovarian cysts was observed in eight (50%), 14 (70%), and eight (67%) patients of groups A, B, and C, respectively. No side effects were observed in either of the three groups. The positive therapeutic effect in group B did not reach statistical significance compared with the two other groups (p > 0.05). Conclusion: A new option of treating large FOCS through a single-dose of a GnRH analogue is proposed and should be carefully considered. Further research is needed in order to evaluate GnRH analogues as an alternative treatment.<\/p>\n